World news and discussion on TalkFuse.
Kids as young as 6 tested in new Wegovy weight loss trial — and there was a troubling side effect
A trial by Wegovy maker Novo Nordisk found that children aged 6 to 11 with obesity lost substantial weight while taking semaglutide. The results could support a request for US approval for this age group in 2027, but the children also grew less during the study, raising questions about possible effects on adult height.
Children received weekly semaglutide or a placebo for two years, alongside diet and exercise counselling. After 18 months, 79% of those taking semaglutide had moved to a lower BMI category and 38% were no longer classed as obese; after two years, their BMI had fallen by 9.4%, while the placebo group’s rose by 8.4%. The semaglutide group grew 1.3 inches less, against typical growth of 4 to 5 inches over two years, and most participants reported side effects, commonly nausea or vomiting. Doctors said longer-term follow-up is needed to understand the growth finding.
In short
- Semaglutide reduced BMI in children aged 6 to 11.
- Children taking it grew 1.3 inches less over two years.
- Doctors say the possible effect on adult height needs study.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The trial suggests semaglutide could substantially reduce obesity in children who may face serious health risks from excess weight. Supporters could argue that, with medical supervision and lifestyle counselling, offering the treatment may help children whose obesity is difficult to address through other means, while further follow-up clarifies the risks.
The case against
The reduced growth observed over two years raises a significant concern because these children are still developing, and the effect on their eventual adult height is not yet known. Critics could argue that common side effects and limited long-term evidence make it prudent to wait for more follow-up before expanding use to children as young as six.
Explained simply
Wegovy is a brand name for semaglutide, a medicine that affects appetite and is used to help treat obesity. Body mass index, or BMI, is a measure based on a person’s height and weight; in children, it is assessed against age-specific ranges.
Obesity in childhood can affect health, and treatment may include support with diet and activity as well as medicine. Children are also still growing, so doctors need to consider how a treatment might affect growth over time, alongside its effects on weight.
The trial involved children aged 6 to 11 and compared semaglutide with a placebo, with both groups receiving diet and exercise counselling. Longer follow-up is needed to clarify what the observed difference in growth could mean for children’s development.